Principles of DNA-Based Gut Microbiota Assessment and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases

Digestive Diseases

Volumn 34, Issue 3, 2016, Pages 279-285

  Cammarota, Giovanni ^a   Pecere, Silvia ^a   Ianiro, Gianluca ^a   Masucci, Luca ^b   Currò, Diego ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Clostridium difficile; Fecal transplantation; Gastrointestinal; Gut microbiota; Inflammatory bowel disease; Metagenomic

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; DNA; PLACEBO; PROBIOTIC AGENT; VANCOMYCIN;

ANTIBIOTIC THERAPY; CHRONIC CONSTIPATION; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; COLON LAVAGE; CROHN DISEASE; DIARRHEA; DNA DETERMINATION; FECAL MICROBIOTA TRANSPLANTATION; FECES; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HIGH THROUGHPUT SEQUENCING; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; IRRITABLE COLON; MICROBIAL COMMUNITY; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RISK FACTOR; THERAPY EFFECT; ULCERATIVE COLITIS; GASTROINTESTINAL DISEASES; METABOLISM; MICROBIOLOGY; TREATMENT OUTCOME;

DNA; FECAL MICROBIOTA TRANSPLANTATION; FECES; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; HUMANS; TREATMENT OUTCOME;

EID: 84971594717     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000443362     Document Type: Review

References (53)

1. Lessa FC, et al: Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372: 825-834.
2. Cammarota G, et al: Fecal microbiota transplantation for the treatment of Clostridium difficile infection: A systematic review. J Clin Gastroenterol 2014; 48: 693-702.
3. Drekonja D, et al: Fecal microbiota transplantation for Clostridium difficile infection: A systematic review. Ann Intern Med 2015; 162: 630-638.
4. Zipursky JS, et al: Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 2012; 55: 1652-1658.
5. Jiang Z-D, et al: Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis 2013; 56: 1059-1060.
6. Bakken JS, et al: Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians. Anaerobe 2013; 24: 20-24.
7. Cammarota G, et al: Fecal microbiota transplantation: A new old kid on the block for the management of gut microbiota-related disease. J Clin Gastroenterol 2014; 48(suppl 1):S80-S84.
8. Sommer F, Bäckhed F: The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 2013; 11: 227-238.
9. Sekirov I, et al: Gut microbiota in health and disease. Physiol Rev 2010; 90: 859-904.
10. Kelly CR, et al: Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 2015; 149: 223-237.
11. Walker AW, et al: Phylogeny, culturing, and metagenomics of the human gut microbiota. Trends Microbiol 2014; 22: 267-274.
12. Qin J, et al: A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
13. Amann RI, et al: Phylogenetic identification and in situ detection of individual microbial cells without cultivation. Microbiol Rev 1995; 59: 143-169.
14. Muyzer G, et al: Profiling of complex microbial populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-amplified genes coding for 16S rRNA. Appl Environ Microbiol 1993; 59: 695-700.
15. Zoetendal EG, et al: Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and hostspecific communities of active bacteria. Appl Environ Microbiol 1998; 64: 3854-3859.
16. Osborn AM, et al: An evaluation of terminalrestriction fragment length polymorphism (T-RFLP) analysis for the study of microbial community structure and dynamics. Environ Microbiol 2000; 2: 39-50.
17. Carey CM, et al: Current and future uses of real-time polymerase chain reaction and microarrays in the study of intestinal microbiota, and probiotic use and effectiveness. Can J Microbiol 2007; 53: 537-550.
18. Rajilic-Stojanovic M, et al: Development and application of the human intestinal tract chip, a phylogenetic microarray: Analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. Environ Microbiol 2009; 11: 1736-1751.
19. Voelkerding KV, et al: Next-generation sequencing: from basic research to diagnostics. Clin Chem 2009; 55: 641-658.
20. Chen K, Pachter L: Bioinformatics for wholegenome shotgun sequencing of microbial communities. PLoS Comput Biol 2005; 1: 106-112.
21. Weinstock GM: Genomic approaches to studying the human microbiota. Nature 2012; 489: 250-256.
22. Langille MG, et al: Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013; 31: 814-821.
23. Kelly CP, LaMont JT: Clostridium difficile-more difficult than ever. N Engl J Med 2008; 359: 1932-1940.
24. Gough E, et al: Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002.
25. Bauer MP, et al: Clostridium difficile infection in Europe: A hospital-based survey. Lancet 2011; 377: 63-73.
26. Kelly CP: Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 2012; 18(suppl 6):21-27.
27. Musgrave CR, et al: Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int J Infect Dis 2011; 15: e438-e448.
28. Nelson RL, et al: Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2011; 9: CD004610.
29. Lo Vecchio A, Zacur GM: Clostridium difficile infection: An update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012; 28: 1-9.
30. van Nood E, et al: Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.
31. Cammarota G, et al: Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41: 835-843.
32. Youngster I, et al: Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: A randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58: 1515-1522.
33. Surawicz CM, et al: Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-498.
34. Debast SB, et al: European Society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20(suppl 2):1-26.
35. Cammarota G, et al: Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med 2015; 163: 487-488.
36. Cammarota G, et al: The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther 2015; 149: 191-212.
37. Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577-594.
38. Bennet JD, Brinkman M: Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989; 1: 164.
39. Ianiro G, et al: Fecal microbiota transplantation in inflammatory bowel disease: Beyond the excitement. Medicine (Baltimore) 2014; 93: e97.
40. Colman RJ, Rubin DT: Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and metaanalysis. J Crohns Colitis 2014; 8: 1569-1581.
41. Moayyedi P, et al: Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015; 149: 102-109.
42. Rossen NG, et al: Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015; 149: 110-118.
43. Vermeire S, et al: Sa1922 pilot study on the safety and efficacy of faecal microbiota transplantation in refractory Crohn's disease. Gastroenterology 2012; 142:S360.
44. Wei Y, et al: Fecal microbiota transplantation improves the quality of life in patients with inflammatory bowel disease. Gastroenterol Res Pract 2015; 2015: 517-597.
45. Bennet SM, et al: Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver 2015; 9: 318-331.
46. Ringel Y, Maharshak N: Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2013; 305:G529-G541.
47. Borody TJ, et al: Bowel-flora alteration: A potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989; 150: 604.
48. Andrews P, et al: Bacteriotherapy for chronic constipation-long term follow-up. Gastroenterology 1995; 108:A563.
49. Pinn DM, et al: Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. Am J Gastroenterol 2014; 109: 1831-1832.
50. Satokari R, et al: Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection-an observational cohort study. Aliment Pharmacol Ther 2015; 41: 46-53.
51. Youngster I, et al: Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014; 312: 1772-1778.
52. Li M, et al: Fecal microbiota transplantation and bacterial consortium transplantation have comparable effects on the re-establishment of mucosal barrier function in mice with intestinal dysbiosis. Front Microbiol 2015; 6: 692.
53. Petrof EO, et al: Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013; 1: 3.